ISTH 2025 Supported Symposia & Presentation Theaters
​

Our Congress program offers several time slots for informing ISTH 2025 participants about the latest research, product developments, and other scientific activities. Supported Symposia are scientific or educational in nature, offering a platform for in-depth presentations and discussions. Meanwhile, Presentation Theaters are designed to provide industry partners with an opportunity to showcase new research findings, share product information, offer live demonstrations, or raise disease awareness among ISTH 2025 Congress delegates. We hope you will take advantage of these valuable opportunities to engage with the global hemostasis and thrombosis community and highlight your latest innovations.​

 

See below for session titles, dates and times.

 

Sunday, June 22, 7:00 – 7:45  |  Supported Symposium​

• From Breakthroughs to Resolution of Bleeds: Hemophilia Inhibitor Patients in the Age of Non-Factor Prophylaxis (Hema Biologics) 
  Room 203 A & B

​

Sunday, June 22, 12:15 – 13:30  |  Supported Symposia

• ☆ Evolving the Standard of Care in the Age of Non-Factor Therapies (Novo Nordisk)
  Room 201

• ☆ A New Dawn in Hemophilia Care: Exploring the Impact of Antithrombin Lowering  (Sanofi)
  Room 202 A & B

• Developing a Novel Ultra-Long Half-Life rFVIII for Hemophilia A (Octapharma)
  Room 204 A, B & C

• Advancements in Pediatric ITP: What You Need to Know (The France Foundation)
  Room 206

• Measuring the Future: Rethinking Laboratory Testing for NonFactor Approaches in Hemophilia (Pfizer)
  Room 209 A, B & C

​

Sunday, June 22, 13:45 - 14:30  |  Presentation Theaters

• ☆ Time to act: A Subcutaneous Prophylactic Option for Both Hemophilia A and B With Inhibitors (Novo Nordisk Healthcare AG)
  Presentation Theater 1

• Prioritizing Joint Health & Physical Activity in Hemophilia A Patients (Roche / Genentech)
  Presentation Theater 2

• Exploring an Advancement in Hemophilia Care With HYMPAVZI™ (Pfizer)
  Presentation Theater 3

• ☆ Achieve Predictability in Hemophilia B Management With Long-lasting Bleed Protection (CSL Behring)
  Presentation Theater 4​

​

Monday, June 23, 7:00 - 7:45  | Supported Symposium

• Understanding Hereditary Factor X Deficiency to Optimize Clinical Management (Kedrion Biopharma Inc.)
  Room 203 A & B

​

Monday, June 23, 12:15 – 13:30  |  Supported Symposia

• Equitable Access to Prophylaxis in Severe VWD vs Severe Hemophilia A? Worth Thinking About (Octapharma)
  Room 201

• ☆ Exploring the Real-world Impact of ALTUVIIIO® [Antihemophilic Factor (Recombinant), Fc-VWF-XTEN Fusion Protein-ehtl] Through Life Transitions (Sanofi)
  Room 202 A & B

• ☆ Exploring Multi-Immune Modulation in the Management of ITP: Current Practices and Future Perspectives (Sanofi)
  Room 204 A, B & C

• Hemophilia Care with Marstacimab: Latest Clinical Data and Future Perspectives (Pfizer)
  Room 206

• Updates in FVllla Mimetics: Advancing Hemophilia Treatment Today and Tomorrow (The France Foundation)
  Room 207 A & B

• ☆ Reaching New Heights: Physician and Patient Perspectives on Gene Therapy (CSL Behring)
  Room 209 A, B & C

 

Monday, June 23, 13:45 – 14:30  |  Presentation Theaters

• Moving Towards Sustained Protection with FVIII in the non-Haemophilia Range (Swedish Orphan Biovitrum AB)
  Presentation Theater 

• ☆ Bridging the Gap: Lab Testing Strategies for Transitioning Patients from DOACs to Unfractionated Heparin
  (Werfen)
  Presentation Theater 2

• ☆ A New Dawn in Hemophilia Care: Clinical Experiences of Antithrombin Lowering (Sanofi)
  Presentation Theater 3

• A Legacy in the Making: HCPs and Community Members Discuss Personal and Collective Experiences in Hemophilia A (Roche / Genentech)
  Presentation Theater 4

​

Tuesday, June 24, 7:00 – 7:45  |  Supported Symposia

• Plasminogen Deficiency: A Rare Multi-Systemic Disorder (Kedrion Biopharma Inc.)
  Room 203 A&B

​​

Tuesday, June 24, 12:15 – 13:30  |  Supported Symposium

• ☆ The Evolution of Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) Management: What’s Next? (Sanofi)
  Room 201

• Entering the Era of Precision Gene Editing for Hemophilia B (Regeneron)
  Room 204 A, B & C

• Evolving Evidence for Factor Concentrates in Surgical Bleeding​​ (Octapharma)
  Room 206

• ☆ Striving Towards Optimal Hemophilia Care Through Patient-Centric Approaches (Novo Nordisk Healthcare AG)
  Room 209 A, B & C

​

Tuesday, June 24, 13:45 - 14:30  |  Presentation Theaters

• Understanding the Role of FVIII in Hemophilia A Hemostasis and Beyond (Octapharma)
  Presentation Theater 1

• When Optimized Anticoagulation for Serious PE Isn't Enough… (Thrombolex, Inc.)
  Presentation Theater 2

• Navigating Treatment Choices in Haemophilia B: What do we Need to Consider? (Swedish Orphan Biovitrum AB)
  Presentation Theater 3

• One Laboratory Platform by Sysmex: The Key to Comprehensive Thrombocytopenia Investigations (Sysmex)
  Presentation Theater 4
   

 

☆ = Promotional bundle partners​